Vonapanitase: Ph III PATENCY-2 amended

Proteon amended the double-blind, placebo-controlled, North American Phase III PATENCY-2 trial of vonapanitase given immediately after radiocephalic AVF to increase enrollment to 500 patients from 300 and to establish secondary patency and fistula use for hemodialysis as co-primary endpoints. Proteon said it believes the changes will allow data from PATENCY-2 and other completed studies to provide the basis for a BLA...